Studies mull easier switches to OTC

Share this article:
Studies mull easier switches to OTC
Studies mull easier switches to OTC

The FDA says it is looking for change in the OTC market that could help move more drugs from prescription to over-the-counter status.

“The requirement to obtain a prescription for appropriate medication (and to make one or more visits to a practitioner) may contribute to under-treatment of certain common medical conditions,” the agency said in the February 23 Federal Register.

FDA says it is looking for information about the technology the industry has on tap that could help patients get greater access without increasing possible risk. These options may include an over-the-counter-but-through-the-pharmacist approach in which a patient doesn't require a prescription, but does need to consult the pharmacist “to ensure appropriate nonprescription use.”

The agency said it is open to allowing FDA-approved diagnostics to match patients to treatment options, but notes that even rigorous pharmacy tutorials or tech have limits and is looking to pinpoint the types of drugs that could be safely used without a prescription.

Success among the prescription-to-OTC categories has been varied. Merck has failed several times to get OTC approval for its statin Mevacor, because surveys shows patients would take the drug even if they didn't need it, and analysts have been temperate in their assessment of an OTC version of Pfizer's Lipitor.

The allergy category has done fairly well, with Sanofi's Allegra (fexofenadine) getting OTC approval in 2011. McNeil's Zyrtec (cetirizine) made the switch in 2008, and Merck's Claritin (loratadine) was put in consumer's prescription-free reach in 2002.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?